Heartflow, Inc. (HTFL): who owns it and who trades it
As of Nov 16, 2026, HTFL insiders reported 40 open-market sales worth $144M and 1 purchase worth $1.1M in the last 12 months, with 20% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bain Capital Life Sciences III General Partner, LLC (10% owner), with $58.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Heartflow
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HTFL
194 funds and institutions reported HTFL shares worth $2.2B at the end of Q2 2026, about 89% of the company. The largest holder is Bain Capital Life Sciences Investors, LLC with 9.8%.
Funds and institutions (13F) 89%Everyone else 11%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8.45M | 9.80% | $248M | -19% |
| Wellington Management Group LLP | 7.86M | 9.12% | $231M | -34% |
| BlackRock, Inc. | 5.20M | 6.03% | $153M | +255% |
| FMR LLC (Fidelity) | 4.82M | 5.59% | $141M | -11% |
| Vanguard Portfolio Management LLC | 3.58M | 4.16% | $105M | +75% |
| Bamco Inc | 3.23M | 3.74% | $94.6M | -16% |
| Vanguard Capital Management LLC | 2.75M | 3.19% | $80.8M | +45% |
| Jupiter Topco LLC | 2.42M | 2.81% | $71M | – |
| Invesco Ltd. | 2.30M | 2.67% | $67.4M | +20% |
| Alliancebernstein L.P. | 1.92M | 2.23% | $46.8M | +57% |
| Point72 Asset Management, L.P. | 1.72M | 2.00% | $50.5M | +220% |
| Summit Partners Public Asset Management, LLC | 1.69M | 1.97% | $49.7M | +90% |
| State Street Corp | 1.47M | 1.70% | $43.3M | +225% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.47M | 1.70% | $43M | +4% |
| Geode Capital Management, LLC | 1.36M | 1.58% | $39.9M | +151% |
| Nuveen, LLC | 1.35M | 1.57% | $39.7M | +5723% |
| California State Teachers Retirement System | 1.29M | 1.50% | $44M | +4293% |
| Morgan Stanley | 1.05M | 1.22% | $31M | +24% |
| UBS Group AG | 975,510 | 1.13% | $28.6M | +127% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 931,160 | 1.08% | $27.3M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HTFL insiders reported $1.1M of open-market purchases and $144M of sales. 20% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 38,900 | $55.74 | $2.2M | Form 4 |
| Nov 9, 2026 | Vikram Verghese | CFO | Sale plan | 3,587 | $53.15 | $191K | Form 4 |
| Oct 22, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 23,933 | $55.01 | $1.3M | Form 4 |
| Oct 12, 2026 | John C.M. Farquhar | CEO | Sale plan | 38,900 | $49.57 | $1.9M | Form 4 |
| Sep 18, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 19,682 | $50.15 | $987K | Form 4 |
| Sep 18, 2026 | Vikram Verghese | CFO | Sale plan | 16,766 | $50.75 | $851K | Form 4 |
| Sep 17, 2026 | Vikram Verghese | CFO | Sale plan | 7,579 | $50.11 | $380K | Form 4 |
| Sep 15, 2026 | Vikram Verghese | CFO | Sale plan | 668 | $50.01 | $33.4K | Form 4 |
| Sep 14, 2026 | Vikram Verghese | CFO | Sale plan | 4,593 | $50.24 | $231K | Form 4 |
| Sep 11, 2026 | Vikram Verghese | CFO | Sale plan | 29,714 | $50.06 | $1.5M | Form 4 |
| Sep 11, 2026 | John C.M. Farquhar | CEO | Sale plan | 3,890 | $50.00 | $194K | Form 4 |
| Sep 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 35,010 | $46.42 | $1.6M | Form 4 |
| Sep 8, 2026 | Vikram Verghese | CFO | Sale plan | 6,640 | $50.03 | $332K | Form 4 |
| Sep 3, 2026 | Vikram Verghese | CFO | Sale plan | 27,540 | $49.69 | $1.4M | Form 4 |
| Sep 2, 2026 | Vikram Verghese | CFO | Sale plan | 5,876 | $50.60 | $297K | Form 4 |
| Aug 21, 2026 | John C.M. Farquhar | CEO | Sale plan | 27,230 | $50.00 | $1.4M | Form 4 |
| Aug 18, 2026 | John C.M. Farquhar | CEO | Sale plan | 32,676 | $45.00 | $1.5M | Form 4 |
| Aug 17, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 9,219 | $41.23 | $380K | Form 4 |
| Aug 14, 2026 | John C.M. Farquhar | CEO | Sale plan | 15,560 | $39.06 | $608K | Form 4 |
| Aug 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $28.31 | $639K | Form 4 |
| Jul 15, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 9,219 | $25.72 | $237K | Form 4 |
| Jul 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $27.75 | $626K | Form 4 |
| Jun 24, 2026 | John C.M. Farquhar | CEO | Sale plan | 38,900 | $35.00 | $1.4M | Form 4 |
| Jun 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $28.50 | $643K | Form 4 |
| May 18, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 9,219 | $28.34 | $261K | Form 4 |
| May 11, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $29.12 | $657K | Form 4 |
| Apr 30, 2026 | Bain Capital Life Sciences III General Partner, LLC +4 | 10% owner | Sale | 892,533 | $29.18 | $26M | Form 4 |
| Apr 30, 2026 | Bain Capital Life Sciences III General Partner, LLC +4 | 10% owner | Sale | 56,224 | $30.05 | $1.7M | Form 4 |
| Apr 29, 2026 | Bain Capital Life Sciences III General Partner, LLC +4 | 10% owner | Sale | 797,133 | $29.37 | $23.4M | Form 4 |
| Apr 28, 2026 | Bain Capital Life Sciences III General Partner, LLC +4 | 10% owner | Sale | 254,110 | $30.51 | $7.8M | Form 4 |
| Apr 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $26.72 | $603K | Form 4 |
| Apr 1, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 64,533 | $24.64 | $1.6M | Form 4 |
| Mar 19, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 64,533 | $25.69 | $1.7M | Form 4 |
| Mar 18, 2026 | John C.M. Farquhar | CEO | Sale plan | 9,725 | $25.00 | $243K | Form 4 |
| Mar 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 12,837 | $22.66 | $291K | Form 4 |
| Mar 5, 2026 | Julie A Cullivan | Director | Sale plan | 9,122 | $25.00 | $228K | Form 4 |
| Feb 12, 2026 | Campbell Rogers | Chief Medical Officer | Sale plan | 65,153 | $24.49 | $1.6M | Form 4 |
| Feb 10, 2026 | John C.M. Farquhar | CEO | Sale plan | 22,562 | $27.46 | $620K | Form 4 |
| Feb 5, 2026 | Julie A Cullivan | Director | Sale plan | 8,000 | $27.32 | $219K | Form 4 |
| Feb 4, 2026 | Bain Capital Life Sciences Investors, LLC +4 | 10% owner | Sale | 2.00M | $28.05 | $56.1M | Form 4 |
| Dec 16, 2025 | Jeffrey C Lightcap | Director | Purchase | 40,000 | $26.34 | $1.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | – | $58.9M | Apr 30, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | $56.1M | Feb 4, 2026 |
| John C.M. Farquhar | Chief Executive Officer, Director | – | $15M | Nov 10, 2026 |
| Campbell Rogers | Chief Medical Officer | – | $8M | Oct 22, 2026 |
| Vikram Verghese | Chief Financial Officer | – | $5.2M | Nov 9, 2026 |
| Jeffrey C Lightcap | Director | $1.1M | – | Dec 16, 2025 |
| Julie A Cullivan | Director | – | $447K | Mar 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HTFL short interest
Moderate short interest. 6.5% of HTFL shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 64%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.69M HTFL shares were sold short, 6.5% of the shares outstanding, down 22.4% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.69M | 6.54% | -22% | 1.62M | 3.5 |
| Oct 15, 2026 | 7.33M | 8.43% | +8% | 1.66M | 4.4 |
| Sep 30, 2026 | 6.81M | 7.84% | +21% | 2.04M | 3.3 |
| Sep 15, 2026 | 5.63M | 6.47% | -7% | 1.84M | 3.1 |
| Aug 31, 2026 | 6.07M | 6.98% | -10% | 2.39M | 2.5 |
| Aug 14, 2026 | 6.78M | 7.80% | -1% | 1.76M | 3.9 |
| Jul 31, 2026 | 6.85M | 7.88% | +17% | 1.04M | 6.6 |
| Jul 15, 2026 | 5.87M | 6.81% | +13% | 1.42M | 4.2 |
| Jun 30, 2026 | 5.18M | 6.00% | +23% | 2.98M | 1.7 |
| Jun 15, 2026 | 4.21M | 4.89% | +16% | 1.15M | 3.7 |
| May 29, 2026 | 3.64M | 4.22% | +5% | 1.25M | 2.9 |
| May 15, 2026 | 3.48M | 4.03% | -20% | 1.05M | 3.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Heartflow company events
Heartflow filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 13, 2026.
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 18, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Heartflow financials
Famous investors that hold HTFL
4 of the 50 well-known investors we track reported holding HTFL in their latest 13F filing. The largest position is Jim Simons's, worth $49.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 993,900 | $49.4M | 0.1% | +160% |
| Israel Englander · Millennium Management | Q3 2026 | 933,918 | $46.5M | 0.0% | +1% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 681,657 | $33.9M | 0.1% | -60% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 287,310 | $14.3M | 0.0% | -64% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named HTFL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BCLS Fund III Investments, LP | 13G/A | 5.1% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 6.4% |
| Nov 16, 2026 | BCLS Fund III Investments, LP | 13G/A | 5.1% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 6.4% |
Questions about Heartflow, Inc. (HTFL) stock
Who owns the most HTFL stock?
The largest reported owner of Heartflow, Inc. (HTFL) is Bain Capital Life Sciences Investors, LLC, with 9.8% of the company. In total, 194 funds and institutions reported holding HTFL at the end of Q2 2026, together about 89% of the shares. See the largest owners.
Are HTFL insiders buying or selling?
In the last 12 months, HTFL insiders reported 1 open-market purchase worth $1.1M and 40 sales worth $144M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in HTFL?
As of Oct 30, 2026, 5.69M HTFL shares were sold short, 6.5% of the shares outstanding, down 22.4% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Which famous investors hold HTFL?
4 of the 50 well-known investors we track reported HTFL in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $49.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.